Zogenix Presents Results of Fintepla’s (fenfluramine) Study Highlighting the Impact of Treatment on Dravet Syndrome Patients, Caregivers, and Families at AAN 2021

Shots:

• The P-III study is designed to assess caregivers’ perspectives on the long-term seizure & non-seizure-related benefits of Fintepla on patients with Dravet syndrome and on their caregivers and families
• Results: seizure-related benefits noted by caregivers include a reduction in frequency, seizure activity, and shorter recovery time while non-seizure benefits include improvements in executive functions such as cognition (76%), learning, problem-solving (56%), mood (41%), sleep quality (47%), motor function (46%) and speech (48%)
• The caregivers themselves felt less stress (66%) anxiety, and depression (68%), with 62% of employed parents missing less work, sleep improved (71%). Family benefits showed improvement in behavior and/or mood of siblings (58%)

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Zogenix